Arcus Biosciences Inc.

Clinical-stage biopharma with a medicinal-chemistry R&D engine building best-in-class oncology and immunology medicines, advanced through risk-sharing partnerships with Gilead, AstraZeneca, and Taiho. Two Phase 3 oncology programs lead the portfolio: casdatifan (HIF-2α inhibitor, PEAK-1 in renal cell carcinoma) and quemliclustat (CD73 inhibitor, PRISM-1 in 1L pancreatic cancer). An expanding oral I&I portfolio (MRGPRX2 antagonist AB102, a TNF inhibitor) is slated to enter the clinic from 3Q26.